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Effects of Sodium Intake, Furosemide, and Infusion of
Atrial Natriuretic Peptide on the Urinary and Metabolic
Clearances of Arginine Vasopressin in Normal Subjects*
ARNOLD M. MOSES, CAROL JONES, AND CAROLYN B. YUCHA
Veterans Administration Medical Center and the Departments of Medicine and Pharmacology, State
University of New York Health Science Center, Syracuse, New York 13210
ABSTRACT. Arginine vasopressin (AVP) and atrial natri-
uretic peptide (ANP) have important influences on water and
electrolyte metabolism, and studies on the interactions between
these hormones may have important implications. We have
investigated the effects of sodium intake, furosemide, and infu-
sion of ANP on the urinary and metabolic (nonurinary) clear-
ances of AVP in hydrated normal subjects. On a high sodium
diet there was an increase in urine volume, sodium excretion,
osmolal clearance, plasma ANP concentration, and urinary
clearance and fractional excretion of AVP, with a decrease in
PRA. The infusion of furosemide increased urine volume, so-
dium excretion, osmolal clearance, and PRA, but decreased
circulating ANP levels and urinary clearance and fractional
excretion of AVP. Since there was a positive correlation between
circulating ANP and urinary clearance of AVP in these experi-
ments, we infused human aANP in physiological amounts and
found increases in the urinary and metabolic (nonurinary) clear-
ances of AVP. The changes in urinary clearance of AVP in all
three experiments occurred even in relation to creatinine clear-
ance. These observations demonstrate that urinary clearance of
AVP does not correlate with urine volume, sodium or solute
excretion, or PRA. The observations support a physiological role
for ANP in modulating the renal action of AVP, probably at the
level of the renal tubules, and indicate a need for caution when
using plasma or urinary AVP as an indicator of AVP release
from the neurohypophysis. (J Clin Endocrinol Metab 70: 222,
1990)
THE INFUSION of arginine vasopressin (AVP) inamounts ranging from 10-350 /iU/kg-min into hy-
drated normal subjects on uncontrolled sodium intakes
causes dose-related increases in urinary AVP concentra-
tion and excretion rate, plasma AVP concentration, and
urinary and metabolic clearances of AVP. In contrast
the fractional excretion of infused AVP was quite con-
sistent (~6.5%) at each infusion rate of AVP (1). The
results of these experiments in man have been very
closely duplicated in conscious dogs (2).
The present studies were designed and conducted in
hydrated normal subjects to clarify the roles of sodium
excretion, solute excretion, urinary volume, plasma vol-
ume, atrial natriuretic peptide (ANP), and PRA on the
metabolic (nonurinary) and urinary clearances of infused
AVP in hydrated normal subjects. Our interest in doing
this was stimulated by the reports that the urinary
clearance of vasopressin is increased in sodium-retaining
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states, such as occurs in patients with primary aldoster-
onism (3) and when desoxycorticosterone is administered
to the pig on an unrestricted sodium intake (4). The
reverse has been demonstrated (decreased urinary clear-
ance of AVP) in the presence of dehydration (3).
Materials and Methods
The project was approved by the Committee for the Protec-
tion of Human Subjects, and informed consent was obtained
from each subject. No subjects were taking medication, includ-
ing oral contraceptives, and female subjects were studied during
the first half of the menstrual cycle. The subjects were in-
structed not to consume alcohol for 48 h or to smoke tobacco
for 12 h before each study. Intravenous cannulas were placed
in both forearms for administration of infusions and withdrawal
of blood samples. Subjects remained recumbent in bed, except
for standing briefly to urinate. Specimens from several subjects
were not assayed or included in the data because they were
unable to consistently empty their bladders, as reflected by
variable creatinine and osmolal clearances. Recordings of blood
pressure and heart rate were made every 5 min using an
automatic device with a self-inflating/deflating cuff and a dig-
ital printout.
Three groups of studies were conducted. The purpose of the
first set of experiments was to investigate the effect of sodium
intake on the metabolism of and response to infused AVP.
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Nine normal subjects (seven males and two females) between
23-37 yr of age (median, 27 yr) were admitted twice to the
Clinical Research Center, University Hospital. Each subject
was studied once on a diet containing 250 meq sodium/day for
4 days and another time, in random order, when they had
consumed 10 meq/day sodium diets for 4 days. At approxi-
mately 0800 h after an overnight fast, each subject was given
an oral water load of 20 mL/kg over 15-20 min. Urine was
passed spontaneously every 15 min, and the volume voided was
replaced orally with tap water. After three consecutive periods
of constant diuresis, synthetic AVP (Pitressin, Parke-Davis,
Morris Plains, NJ), diluted in normal saline, was infused over
consecutive periods of 1 h at each of the following rates: 10, 35,
and 100 ^U/kg-min. During the AVP infusion subjects voided
every 30 min, and the voided volume was replaced with tap
water minus the amount infused over the 30-min period. Blood
for AVP, PRA, ANP, osmolality, and creatinine determinations
was obtained at 30 and 60 min of each infusion rate. We had
previously demonstrated under these conditions that plasma
levels of AVP at 30 and 60 min of each infusion rate of AVP
were similar, and therefore, an equilibrium state existed from
30-60 min of each infusion rate (1). The urine data used in the
calculations are from the second 30-min collection period of
each infusion rate.
The second group of studies concerned the effect of furose-
mide on the response to infused AVP. Nine normal subjects
(eight males and one female) between 23-36 yr of age (median,
27 yr), including five who were investigated for the effect of
sodium intake, were twice placed on 250-meq sodium diets for
4 days. The experiments proceeded as described above (but
with two rates of AVP infusion), except that each subject was
once infused with 40 mg furosemide iv over a 5-min period at
the beginning of the first rate of infusion of AVP.
The third group of studies was undertaken to determine the
effect of infused ANP on the response to AVP. Ten normal
subjects (6 males and 4 females) between 22-40 yr of age
(median, 26.5 yr), different from those investigated in the
above-described studies, were placed on 50-meq sodium diets
FlG. 1. The effect of dietary sodium in-
take on the response to infused ANP in
three different amounts for 1 h each. The
studies were conducted in nine normal
subjects who had consumed either 10 or
250 meq sodium/day. PRA (B) may be
converted to nanograms per (L-s) by
multiplying nanograms per mL/h by
0.2778. The P values refer to the effect
of diet at all infusion rates of AVP, based
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TABLE 1. Data obtained from infusion of AVP into nine hydrated
normal subjects who consumed two different sodium diets for 4 days
Dietary Na
(meq/day)










































2.06 ± 0.39 1.26 ± 0.20 0.87 ± 0.13 <0.001
0.81 ± 0.10 0.60 ± 0.09 0.54 ± 0.11
612 ± 60 734 ± 32 815 ± 33 NS
606 ± 42 689 ± 39 748 ± 44
3.94 ± 0.43 3.18 ± 0.38 2.49 ± 0.30 <0.001
1.70 ± 0.17 1.43 ± 0.18 1.41 ± 0.30
126 ± 6 129 ± 8 124 + 6 NS
118 ±8 118 ± 13 126 ± 12
75 ± 7 58 ± 10 52 ± 10 NS
80 ±11 68 ± 11 66 ± 10
1.4 ± 0.2 2.7 ± 0.3 5.9 ± 0.7 NS
1.2 ± 0.2 2.6 ± 0.2 6.8 ± 0.5
76 + 13 193 ± 23 469 ± 64 NS
45 ± 5 160 ± 25 385 ± 60
.102 ± .018 .074 + .009 .062 ± .008 <0.003
.061 ± .007 .060 ± .010 .051 ± .008
8.30 ± 1.77 14.1 + 2.01 17.9 ± 2.12 NS









124 ± 5 <0.005
116 ±3
57 ± 4 NS
57 + 2
Values are the mean + SEM. P values refer to the effect of diet at all
infusion rates of AVP, based on analysis of variance for repeated
measures.
for 4 days. They were given the same maintained 20 mL/kg
water load as above and then infused with AVP at the rate of
35 ftU/kg-min for 2.5 h. During the last hour they were also
infused with 20 /ug of the 28-amino acid peptide human aANP
(lot FH ANP 28O285C, Bachem, Inc., Torrance, CA). Urine
and blood samples were collected as described for the above
experiments (except for PRA). The same experiment was sub-
sequently conducted in 9 additional normal subjects (7 males
and 2 females) between 23-42 yr of age (median, 25 yr), but
with the infusion of 40 /*g ANP. The use of ANP was approved
by an IND from the FDA. Before use, the ANP was appropri-
ately diluted, filtered, and checked for sterility and the absence
of pyrogenicity.
Blood for AVP assay was collected into evacuated glass tubes
containing EDTA, chilled immediately, and centrifuged, and
the plasma was stored at —20 C for no longer than 2 months.
When ready for assay, the plasma was thawed, and the pH
adjusted by the addition of 0.1 mL 1 N HCl/mL. Urine for AVP
assay was acidified to pH 3.5 with glacial acetic acid and stored
at —20 C. Thawed specimens for assay were extracted on Sep-
Pak Cis columns (Waters Associates, Milford, MA) using ab-
solute methanol for the elution. The RIA was conducted using
Ferring K3 antibody (Ferring Pharmaceuticals, New York, NY)
and [125I] AVP (DuPont/New England Nuclear Research Prod-
ucts, Boston, MA). The standard curves were constructed from
the same batch of AVP that was infused. The maximum sen-
sitivity of the RIA standard curve was 0.4 ^U/mL (0.15 fill/
assay tube). Intra- and interassay coefficients of variation were
4.6% and 6.8%, respectively.
Extracted recovery of AVP ranged from 83.0-91.5%. The
concentration of urine before extraction had little or no effect
on the amount of AVP extracted. The AVP obtained from the
infusion tubing was assayed and found to have the calculated
potency, indicating that no AVP adhered to the plastic bag or
tubing.
For measurement of plasma ANP 10 mL blood were collected
in EDTA tubes on ice and spun within 1 h in a refrigerated
centrifuge. The plasma was stored at —20 C. Within the next 2
weeks the plasma was thawed and spun at 4 C. The supernatant
was decanted and pipetted into plastic tubes containing 0.1 N
HC1 in the ratio of 0.1 mL/mL plasma, centrifuged, and de-
canted onto Sep-Pak Ci8 cartridges, prepared by sequential
washing with 5 mL 100% methanol and 10 mL distilled water.
A distilled water wash of 10 mL was followed by a second wash
of 5 mL 4% trifluoroacetic acid. The ANP was then elutedwith
5 mL 90% ethanol containing 4% trifluoroacetic acid. The
eluate was dried with air at room temperature and stored at
—20 C until assayed.
For RIA of human aANP, we used antibody and [125I]ANP
from Peninsula Laboratories (Belmont, CA; catalog no. RAS
8798 and Y8798, respectively). The antiserum was incubated
first in the presence of standard or sample for 24 h and then
with labeled ANP for an additional 16 h, both at 4 C. Free and
bound aANP were separated by incubating with goat antirabbit
immunoglobulin G serum and normal rabbit serum for 2 h at
room temperature and then centrifuging. The maximum sen-
sitivity of the RIA was 2.5 pg/mL (2 pg/assay tube). Total
binding at the antibody dilution used was 30-40%. Intra- and
interassay coefficients of variation were 7.5% and 9.5%, respec-
tively. Recovery of ANP through extraction of ANP from blood
ranged from 81.8-88.3%.
Plasma concentrations of PRA were determined by using the
angiotensin-1-Biotecx Radioimmunoassay Kit (Biotecx Labo-
ratories, Inc., Friendswood, TX). Osmolality was determined
by freezing point depression using an Advanced Instruments
Digimatic Osmometer (Advanced Instruments, Needham, MA).
Creatinine concentrations were determined using a Techni-
con AutoAnalyzer. Sodium and potassium concentrations were
determined by flame photometry.
The MCRs of AVP were determined by dividing the infusion
rates of AVP in microunits per kg/min by the mean plasma
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FlG. 2. The effect of furosemide on the
response to infused AVP in different
amounts for 1 h each. The studies were
conducted in nine normal subjects who
had been eating 250-meq/day sodium
diets. The conversion factor for PRA is
explained in Fig. 1. The P values refer
to the effect of the diuretic at both in-
fusion rates of AVP, based on analysis
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AVP (in microunits per mL) at 30 and 60 min of each infusion
rate. This calculation is valid because endogenous secretion of
AVP is minimal in the water-loaded state. To obtain the true
(nonurinary) MCR of AVP (Tables 1, 2, and 3), urinary clear-
ance of AVP was subtracted. Plasma PRA and ANP values
(Figs. 1, B and C; 2, B and C; and 3B) are means of specimens
collected at 30 and 60 min of each infusion rate of AVP.
Laboratory determinations from paired studies were ana-
lyzed by analysis of variance for repeated measures to deter-
mine the effect of treatment at all infusion rates of AVP. The
effects of AVP plus ANP vs. AVP alone were analyzed by
paired one-tailed t tests based on the hypothesis that ANP
would increase AVP clearance and the associated phenomena.
Results
When subjects consumed the high sodium diet (250
meq/day), urine volume, sodium excretion, and solute
clearance were significantly greater during the AVP in-
fusion than when they consumed the low sodium (10
meq/day) diet (Fig. 1A). The high sodium diet caused a
decrease in PRA and an increase in circulating ANP
10 35
AVP Infusion Rate (nil kg /min)
levels (Fig. 1, B and C). When on the high sodium diet,
urinary clearance of infused AVP was greater (Fig. ID),
even factored for creatinine clearance (Fig. IE). The high
sodium diet caused the fractional excretion of infused
AVP and the systolic blood pressure to be increased
(Table 1). Heart rate did not change with a change in
either diet or AVP infusion rate.
Administration of furosemide to subjects receiving the
250 meq/day sodium diet markedly increased urine vol-
ume, sodium, potassium, and osmolal clearance during
the AVP infusion studies (Fig. 2A and Table 2). Con-
versely, the furosemide decreased urine osmolality (Table
2). Furosemide increased the PRA and decreased circu-
lating ANP levels (Fig. 2, B and C). Furosemide de-
creased the urinary clearance of infused AVP (Fig. 2D),
even in relation to creatinine clearance (Fig. 2E). Furo-
semide caused the fractional excretion of AVP to be
decreased, and it increased diastolic blood pressure (Ta-
ble 2). There were no changes in heart rate when furo-
semide was given or when the AVP infusion rate was
altered.
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1.14 + 0.16 <0.001
5.78 + 0.64
731 ± 29 <0.001
358 ± 11
2.98 + 0.39 <0.001
7.45 ± 0.69
132 + 10 NS
127 ± 27
58 ± 8 O.001
137 ± 12
2.4 + 0.2 NS
2.7 + 0.3
213 + 35 NS
161 + 22
.079 + .012 <0.05
.060 + .007








Values are the mean + SEM. P values refer to the effect of furosemide
at all infusion rates of AVP, based on analysis of variance for repeated
measures.
Both rates of infusion of ANP (20 and 40 /ug/h) into
subjects being infused with AVP caused increases in
urine volume, osmolal clearance, urine sodium excretion,
urine AVP excretion per min, urinary clearance of AVP
(in milliliters per min and in relation to creatinine clear-
ance), fractional excretion of infused AVP, and plasma
ANP concentration (Fig. 3, A-D, and Table 3). Both
rates of ANP infusion decreased urine potassium excre-
tion (Table 3). In contrast, only the 40-/ug infusion of
ANP decreased plasma AVP and increased urine osmo-
lality and the MCR (nonurinary) of AVP (Table 3).
There was no change in heart rate when 20 ̂ g ANP were
infused. However, heart rate increased 5 beats/min dur-
ing infusion of 40 jug ANP (P < 0.005).
Plasma levels of ANP were compared at 30 and 60 min
of each infusion rate of ANP (20 and 40 /ug/h), and there
were no differences at the two time intervals (change,
+2.6 ± 7.6 pg/mL; P = NS). Therefore, an equilibrium
state existed from 30-60 min during the ANP infusions.
Discussion
These studies, which were conducted in hydrated nor-
mal subjects under steady state conditions of AVP infu-
sion, demonstrate that the increased urinary sodium
excretion, osmolal clearance, and urine volume caused
by a high sodium intake (250 vs. 10 meq/day) are asso-
ciated with increased urinary clearance of AVP. In con-
trast, a much greater natriuresis, solute excretion, and
urine volume caused by furosemide is associated with a
decreased urinary clearance of AVP. The fractional ex-
cretion of AVP in each experiment was changed signifi-
cantly in the same direction as the urinary clearance of
AVP. It is possible that furosemide per se decreased
urinary clearance of AVP. Nonetheless, these observa-
tions do not support the suggestion that the urinary
excretion and clearance of AVP are closely correlated
with solute clearance (5).
Plasma volume is expected to be expanded when sub-
jects consume high sodium diets us. low sodium diets.
This is confirmed by the decreased circulating PRA
values and increased circulating ANP (6-8). Conversely
plasma volume is expected to be contracted during fu-
rosemide-induced diuresis. This is confirmed by the find-
ing that circulating PRA was increased and ANP was
decreased (8-10). The urinary clearance of AVP in these
experiments correlates with the plasma volume changes
and circulating ANP levels. Changes in MCRs (nonuri-
nary) of AVP induced by the high sodium diet and by
furosemide are in the same direction as changes in uri-
nary clearances, but are not statistically significant. The
increased urinary clearance of AVP caused by plasma
volume expansion in our studies may explain the in-
creased urinary clearance of vasopressin in deoxycorti-
costerone-treated pigs (4) and in patients with primary
aldosteronism (3) noted in the Introduction.
Since the urinary clearance of AVP correlated with
endogenously attained ANP levels, we infused ANP in
amounts that we estimated would attain plasma levels
that would produce physiological effects in normal sub-
jects (11,12). The levels of ANP attained increased urine
volume, sodium excretion, and osmolal clearance and
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FIG. 3. The effect of infusing 20 Mg ANP
over 1 h on the response to AVP infused
at the rate of 35 MU/kg • min. The studies
were conducted in 10 normal subjects
who had been eating 50-meq/day sodium
diets. The mean plasma ANP level at-
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also increased AVP excretion, fractional excretion, and
urinary clearance of AVP. The infusion of 40 pg ANP
lowered plasma AVP levels and increased the MCR of
AVP. The changes in urinary clearance of AVP that were
caused by alterations in plasma volume (diet or diuretic)
or by infusion of ANP were significant even when fac-
tored for creatinine clearance. Therefore, the effect of
altered plasma volume and/or ANP may be exerted at
the level of the renal tubules. Binding sites for ANP are
present in proximal tubules, outer medulla, and inner
medullary collecting ducts (13). Chai et al. (14) have
described receptors in the inner and outer renal medulla
of the rat. Alterations in urinary clearance of AVP by
tubular actions are possible because there is considerable
evidence that after vasopressin is filtered through the
glomerulus it is reabsorbed or degraded proximally and
secreted distally (15, 16). The proximal tubular actions
apparently involve two mechanisms, one involving hy-
drolysis by luminal peptidases, and another involving
endocytosis with transfer of the hormone to lysosomes
and rapid degradation therein (17). Since our calcula-
tions of the MCR of AVP exclude urinary clearance, the
increase in the MCR of AVP that resulted from the
infusion of 40 fj.g ANP would apparently result from
increased visceral metabolism of AVP. In dog experi-
ments, liver and prehepatic viscera, presumably intes-
tine, account for most of the metabolism of AVP, al-
though there may be substantial clearance of AVP by
other organs (18).
Despite the known vasodilatory action of ANP, the
infusion of ANP caused no change in blood pressure,
which was also noted by Cody et al. (19) in supine normal
subjects infused with much larger amounts of ANP.
Twenty micrograms of ANP did not alter the pulse rate.
However, the infusion of 40 ng ANP increased the pulse
rate by 5 beats/min, which could be a subtle consequence
of vasodilatation. Both rates of infusion of ANP de-
creased the rate of potassium excretion. This effect of
AVP has previously been observed in man (20) and could
be due to increased distal tubular sodium potassium
exchange.
ANP inhibits the release of AVP in vitro (21), and
ANP also has been claimed to inhibit AVP release in
man under basal conditions and in response to osmotic
and postural stimuli (22-24). The evidence for this con-
cept is the presence of lower plasma AVP levels when
ANP is infused. Our present observations should cause
a reassessment of the postulated inhibition of AVP re-
lease by ANP, since the ANP might have lowered circu-
lating AVP levels by increasing its clearance. In addition,
there is increasing evidence that ANP may exert direct
renal actions as part of the mechanism by which this
hormone increases the excretion of water (in addition to
sodium) (14). ANP inhibits AVP-stimulated water trans-
port in rabbit collecting tubules perfused in vitro (25). A
similar observation has been reported using the rat inner
medullary collecting duct (26). Although our studies did
not reveal an antagonism between ANP and the antidi-
uretic action of AVP, other studies in man, using 5-10
times as much ANP, have demonstrated such an action
of ANP (27, 28). These observations suggest that in
addition to its role in sodium balance, ANP may act as
a hormone of water homeostasis by antagonizing the
antidiuretic action of AVP. Our results suggest that ANP
may, as part of its effect on water homeostasis, increase
the urinary clearance and perhaps the metabolic clear-
ance of AVP. This mechanism may be responsible for
the renal resistance to AVP that occurs in the deoxycor-
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TABLE 3. Effect of infusing 20 and 40 ng ANP during 1 h on the action















































0.74 ± 0.11 <0.01 0
1.19 ± 0.19 +
748 ±41 NS 0
730 ±26 +
1.88 ± 0.23 <0.005 0
2.98 ± 0.43 +
113 ±17 NS 0
111 ±10 +
103 ± 16 <0.01 0
193 ±26 +
72 ± 12 <0.05 0
51 ±7 +
3.0 ± 0.2 NS 0
2.9 ± 0.2 +
218 ± 42 <0.0005 0
274 ±48 +
70.9 ± 9.0 <0.0005 0
92.7 ± 10.0 +
0.68 ± 0.08 <0.05 0
0.89 ± 0.10 +







































0 11.2 ± 0.73 NS 0 12.6 ± 1.46 <0.05
+ 11.2 ± 0.71 + 15.0 ± 2.07
Plasma ANP (pg/mL)
0 16.1 ± 2.3 <0.0005 0 12.7 ± 1.2 <0.0005
+ 54.9 ± 3.3 + 71.5 ± 3.1
Systolic blood pres-
sure (mm Hg)
0 114 ± 4 NS 0 115 ± 3 NS
-1- 115 ±4 + 1 1 7 + 2
Diastolic blood pres-
sure (mm Hg)
0 70 + 3 NS 0 67 ± 3 NS
+ 68 ±2 + 68 + 2
Values are the mean + SEM. P values refer to the effect of either 20 or 40 ng
ANP on the various measurements (by paired one-tailed t test).
ticosterone-treated dog (29).
The circulating levels of ANP, on either a high or low
sodium intake, are similar at each rate of infusion of
AVP and to that measured before AVP was infused (7.0
± 1.3 pg/mL on low sodium intake and 16.9 ± 3.2 pg/
mL on high sodium intake). Since the plasma AVP levels
attained in these experiments cover the usual physiolog-
ical range (in the absence of hypovolemia or hypoten-
sion), our data do not support the concept that in man
AVP exerts a physiological role in stimulating the release I
of ANP, as has been observed in vitro (30) and in intact
rats (31) and dogs (32). In contrast, when the PRA was I
stimulated by the low sodium diet to 1.58 ± 0.36 ng/(L
s) before the infusion of AVP, there was a progressive |
decline in PRA with increasing infusion rates of AVP (P I
< 0.005). This is consistent with the observations that [
AVP inhibits renin release in rats (33), dogs (34), and I
man (35).
In summary, these experiments demonstrate that in
hydrated normal subjects infused with AVP, the admin- I
istration of a high sodium diet and furosemide results in
a positive correlation between urinary clearance of AVP I
and plasma ANP concentration, but not with urine vol-
ume, sodium or solute excretion, or PRA. Since the
infusion of physiological amounts of human aANP in- I
creases urinary clearance and perhaps metabolic (nonu- I
rinary) clearance of AVP, we believe that ANP may play I
a role in modulating the renal action of AVP. Our obser-
vations also indicate that endogenous ANP levels should
be considered when using either plasma or urinary AVP
as an indicator of AVP release from the neurohypophysis I
(36-38).
Acknowledgments
The authors acknowledge the expert technical assistance of Rose-
mary Fenner. They are also grateful for the expert care provided by I
the nursing staff of the Clinical Research Center.
References
1. Moses AM, SteciakE. Urinary and metabolic clearances of arginine I
vasopressin in normal subjects. Am J Physiol. 1986;251:R365-70. I
2. Sondeen JL, Claybaugh JR. Clearance and urinary excretion of I
vasopressin in conscious dogs. Am J Physiol. 1989;256:R291-8.
3. Horky K, Sramkova J, Widimsky Jr J, Dvorakova J. Plasma
concentration and urinary excretion of arginine-vasopressin in j
primary aldosteronism during the fluid deprivation tests. Exp Clin
Endocrinol. 1983;82:347-55.
4. Brooks DP, Crofton JT, Share L, et al. Increased urinary vaso-
pressin excretion in the DOCA-hypertensive pig. Clin Exp Hyper-
tension Theory Pract. 1983(Suppl 10):1717-34.
5. Robertson GL. The regulation of vasopressin function in health
and disease. Recent Prog Horm Res. 1977;33:333-74.
6. Sagnella GA, Markandu ND, Shore AC, MacGregor GA. Effects of
changes in dietary sodium intake and saline infusion on immuno-
reactive atrial natriuretic peptide in human plasma. Lancet.
1985;2:1208-10.
7. Brown JJ, Davies DL, Lever AF, Robertson JIS. Variations in
plasma renin concentration in several physiological and patholog-
ical states. Can Med Assoc J. 1964;90:201-6.
8. Williams GH, Cain JP, Dluhy RG, Underwood RH. Studies of the
control of plasma aldosterone concentration in normal man. 1.
Response to posture, acute and chronic volume depletion, and
sodium loading. J Clin Invest. 1972;51:1731-41.
9. Kimura T, Abe K, Ota K, et al. Effects of acute water load,
hypertonic saline infusion, and furosemide administration on atrial
natriuretic peptide and vasopressin release in humans. J Clin
Na INTAKE, FUROSEMIDE, AND ANP AND AVP CLEARANCE 229
Endocrinol Metab. 1986;62:1003-10.
10. Anderson Jr GH, Miller M, Blakeman N, Streeten DHP. Effect of
volume depletion and repletion on plasma concentrations of atrial
natriuretic hormone in essential hypertension. In: Brenner B,
Laragh J, eds. Advances in atrial peptide research. Am Soc Hyper-
tension Symp Ser. New York: Raven Press; 1988;2:547-52.
11. Richards AM, Tonolo G, Montorsi P, et al. Low dose infusions of
26- and 28-amino acid human atrial natriuretic peptides in normal
man. J Clin Endocrinol Metab. 1988;66:465-72.
12. Richards AM, McDonald D, Fitzpatrick MA, et al. Atrial natri-
uretic hormone has biological effects in man at physiological
plasma concentrations. J Clin Endocrinol Metab. 1988;67:1134-9.
13. Kramer HJ. Atrial natriuretic hormones. Gen Pharmacol.
1988;19:747-53.
14. Chai SY, Sexton PM, Allen AM, et al. In vitro autoradiographic
localization of ANP receptors in rat kidney and adrenal gland. Am
J Physiol. 1986;250:F753-7.
15. Walter R, Bowman RH. Mechanism of inactivation of vasopressin
and oxytocin by the isolated perfused rat kidney. Endocrinology.
1973;92:189-93.
16. Kimura T, Share L. Characterization of the renal handling of
vasopressin in the dog by stop-flow analysis. Endocrinology.
1981;109:2089-94.
17. Carone FA, Christensen El, Flouret G. Degradation and transport
of AVP by proximal tubule. Am J Physiol. 1987;253:F1120-8.
18. Share L, Kimura T, Matsui K, et al. Metabolism of vasopressin.
Fed Proc. 1985;44:59-61.
19. Cody RJ, Atlas SA, Laragh JH, et al. Atrial natriuretic factor in
normal subjects and heart failure patients. J Clin Invest.
1986;78:1362-74.
20. Groban L, Ebert TJ, Kreis DU, et al. Hemodynamic, renal, and
hormonal responses to incremental ANF infusions in humans. Am
J Physiol. 1989;256:F780-6.
21. Crandall ME, Gregg CM. In vitro evidence for an inhibitory effect
of atrial natriuretic peptide on vasopressin release. Neuroendocri-
nology. 1986;44:439-45.
22. Fujio N, Ohashi M, Nawata H, et al. Alpha-human atrial natriuretic
polypeptide reduces the plasma arginine vasopressin concentration
in human subjects. Clin Endocrinol (Oxf). 1986;25:181-7.
23. Allen MJ, Ang VTY, Bennett ED, Jenkins JS. Atrial natriuretic
peptide inhibits osmolality-induced arginine vasopressin release in
man. Clin Sci. 1988;75:35-9.
24. Williams TDM, Walsh KP, Lightman SL, Sutton R. Atrial natri-
uretic peptide inhibits postural release of renin and vasopressin in
humans. Am J Physiol. 1988;255:R368-72.
25. Dillingham MA, Anderson RJ. Inhibition of vasopressin action by
atrial natriuretic factor. Science 1986;231:1572-3.
26. Nonoguchi H, Sands JM, Knepper MA. Atrial natriuretic factor
inhibits vasopressin-stimulated osmotic water permeability in rat
inner medullary collecting duct. J Clin Invest. 1988;82:1383-90.
27. Brown J, Forsling ML, Valdes G, et al. Antagonism of V2-receptor
effect of antidiuretic hormone by atrial natriuretic peptide in man.
Experientia. 1988;44:513-6.
28. Vierhapper H, Nowotny P, Waldhausl W. Effect of human atrial
natriuretic peptide on l-deamino-D-Arg8-vasopressln-induced an-
tidiuresis in man. J Clin Endocrinol Metab. 1988;66:124-7.
29. Gullner HG, West D, Gill Jr JR, Robertson GL. Diabetes insipidus
with renal resistance-to vasopressin in the desoxycorticosterone-
treated dog: a possible role for prostaglandins. Renal Physiol
(Basel). 1987;10:40-6.
30. Sonnenberg H, Veress AT. Cellular mechanism of release of atrial
natriuretic factor. Biochem Biophys Res Commun. 1984;124:443-
9.
31. Itoh H, Nakao K, Yamada T, et al. Modulatory role of vasopressin
in secretion of atrial natriuretic polypeptide in conscious rats.
Endocrinology. 1987;120:2186-8.
32. Inoue M, Kimura T, Ota K, et al. Effect of vasopressin on atrial
natriuretic peptide release and renal function in dogs. Am J Phys-
iol. 1988;255:E449-55.
33. Henderson IW, Balment RJ, Oliver JA. Vasopressin effects on
plasma renin activity in male and female rats. Clin Sci Mol Med.
1978;55:301-7.
34. Johnson MD, Kinter LB, Beeuwkes R. Effects of AVP and DDAVP
on plasma renin activity and electrolyte excretion in conscious
dogs. Am J Physiol. 1979;236:F66-70.
35. Khokhar AM, Slater JDH, Forsling ML, Payne NN. Effects of
vasopressin on plasma volume and renin release in man. Clin Sci
Mol Med. 1976;50:415-24.
36. Arisaka O, Shimura N, Hosaka A, et al. Water intoxication in
asthma assessed by urinary arginine vasopressin. Eur J Pediatr.
1988;148:167-9.
37. Miller M, Moses AM. Urinary antidiuretic hormone in polyuric
disorders and in inappropriate ADH syndrome. Ann Intern Med.
1972;77:715-21.
38. Moses AM. Clinical and laboratory observations in the adult with
diabetes insipidus and related syndromes. Front Horm Res.
1985;13:156-75.
